Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
D Zheng, X Ye, MZ Zhang, Y Sun, JY Wang, J Ni… - Scientific reports, 2016 - nature.com
Abstract EGFR T790M mutation occurs in half of non-small cell lung cancer (NSCLC)
patients with acquired EGFR-TKI (TKI) resistance, based on tumor re-biopsies using an …
patients with acquired EGFR-TKI (TKI) resistance, based on tumor re-biopsies using an …
Optimization of dosing for EGFR-mutant non–small cell lung cancer with evolutionary cancer modeling
Non–small cell lung cancers (NSCLCs) that harbor mutations within the epidermal growth
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
factor receptor (EGFR) gene are sensitive to the tyrosine kinase inhibitors (TKIs) gefitinib …
[HTML][HTML] Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions
GR Oxnard, PC Lo, M Nishino, SE Dahlberg… - Journal of Thoracic …, 2013 - Elsevier
Introduction Exon 20 insertions are the third most common family of epidermal growth factor
receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known …
receptor (EGFR) mutations found in non–small-cell lung cancer (NSCLC). Little is known …
[HTML][HTML] The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Results Forty-two patients had tissue specimens taken after acquiring resistance to afatinib.
The sensitizing EGFR mutation were all consistent between pre-and post-afatinib tissues …
The sensitizing EGFR mutation were all consistent between pre-and post-afatinib tissues …
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation …
K Park, CJ Yu, SW Kim, MC Lin, V Sriuranpong… - JAMA …, 2016 - jamanetwork.com
Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …
[HTML][HTML] Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed …
AY Helena, CS Sima, J Huang, SB Solomon… - Journal of Thoracic …, 2013 - Elsevier
Background Development of acquired resistance limits the utility of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung …
receptor (EGFR) tyrosine kinase inhibitors (TKI) for the treatment of EGFR-mutant lung …
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer
JF Gainor, AT Shaw - Journal of clinical oncology, 2013 - ascopubs.org
The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib …
Purpose: Treatment of patients with oncogene-addicted cancers with tyrosine kinase
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
inhibitors (TKI) is biologically and clinically different than with cytotoxic chemotherapy. We …
Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers
Deregulation of many kinases is directly linked to cancer development and the tyrosine
kinase family is one of the most important targets in current cancer therapy regimens. In this …
kinase family is one of the most important targets in current cancer therapy regimens. In this …
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
The management of non–small cell lung carcinoma (NSCLC) has been transformed by the
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …
observation that lung adenocarcinomas harboring mutations in epidermal growth factor …